The nation of Zimbabwe has rejected a substantial American healthcare agreement valued at $367m (272 million pounds) over five years because of the United States' demand for confidential information.
The decision came to light following a government memo from December was disclosed, revealing that President Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official spokesperson later explained that the US was requesting health data for research and commercial gain while was unwilling to guarantee the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further talks to secure a agreement suitable to all parties so the country's critical HIV programme can proceed.
Wider Implications
This rejection follows a comparable case in Kenya, where a court halted a similar deal with the US following legal challenges were filed about the security of citizens' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government agreements to boost openness and accountability.
As per reports, 16 nations in Africa have to date signed these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment through US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent promise of access to any medical innovations – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery with no assurance that the end products would be available to our citizens if a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were upending systems previously set up via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This framework is designed to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future co-operation might be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
Medical experts stated it understood the official position, but suggested that negotiations must proceed since much of the country's Aids initiatives depended on international support.
"Where specific concerns arise, such as those relating to data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group said.
This impasse highlights the ongoing tensions between receiving vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.